Breaking News

AbbVie, Simcere Zaiming Partner to Develop Trispecific Antibody in Multiple Myeloma

SIM0500 has shown strong T cell cytotoxicity against MM cells by leveraging a combination of various antitumor effects.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to develop SIM0500, an investigational new drug candidate in Phase 1 trials in relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics